NCT06332131View on ClinicalTrials.gov

Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

Enrolling by invitationOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Coronary Microvascular DysfunctionCardiotoxicityBreast CancerLung Cancer (NSCLC)
Trial Locations (1)

19104

Abramson Cancer Center at University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER